Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) FCF Margin (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed FCF Margin for 16 consecutive years, with 5.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 595889.0% year-over-year to 5.05%, compared with a TTM value of 29.24% through Dec 2025, up 1950016.0%, and an annual FY2025 reading of 18.91%, up 1317174.0% over the prior year.
  • FCF Margin was 5.05% for Q4 2025 at Arrowhead Pharmaceuticals, up from 0.73% in the prior quarter.
  • Across five years, FCF Margin topped out at 782.38% in Q1 2021 and bottomed at 5953.84% in Q4 2024.
  • Average FCF Margin over 5 years is 628.04%, with a median of 84.19% recorded in 2021.
  • The sharpest move saw FCF Margin crashed -349325bps in 2023, then soared 595889bps in 2025.
  • Year by year, FCF Margin stood at 244.49% in 2021, then soared by 41bps to 143.19% in 2022, then plummeted by -2440bps to 3636.44% in 2023, then tumbled by -64bps to 5953.84% in 2024, then surged by 100bps to 5.05% in 2025.
  • Business Quant data shows FCF Margin for ARWR at 5.05% in Q4 2025, 0.73% in Q3 2025, and 557.16% in Q2 2025.